STAT3 was reported to be a potential immunotherapy biomarker in oncogene-addicted NSCLC and elucidation of the role of KLB in NSCLC metastases via regulation of STAT3 should be further investigated 41, 42. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.